Enhua Pharmaceutical (002262.SZ): Class 1 innovative drug NH302 injection approved for clinical trials

Zhitong Finance App News, Enhua Pharmaceutical (002262.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for Class 1 chemical NH302 injections approved and issued by the State Drug Administration, and will conduct clinical trials in the near future. NH302 is a peripheral selective kappa receptor agonist. Preclinical trial results show that NH302 has strong stimulatory activity on kappa receptors, has good analgesic effects on many animal models of pain, has a low effective dose, long action time, and large sedation safety window. It is expected to be developed as an acute pain treatment with obvious clinical advantages.